COMMIT is a phase III randomized trial for people diagnosed with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colon cancer.
Patients must not have received prior systemic therapy for metastatic disease.
The trial is studying how safe and effective the immunotherapy treatment Atezolizumab is when given alone, compared to Atezolizumab when combined with FOLFOX6 and Bevacizumab.
The use of Atezolizumab, with or without the addition of FOLFOX6 and Bevacizumab, is experimental. Because of that, not all risks are known before starting a clinical trial.
The COMMIT study is currently enrolling people diagnosed with metastatic MSI-H or dMMR colorectal cancer. Patients must not have been previously treated with any systemic therapy for their metastatic cancer.
Metastatic cancer is cancer that has spread to parts of the body away from the colon or rectum, such as the bones or liver.
MSI-H (microsatellite instability) and dMMR (deficient DNA mismatch repair) are unique features (“biomarkers”) of some colorectal cancers. To learn more about testing for these types of biomarkers, see our Diagnostic and Surveillance Testing Learning Center.
Phase: Phase III
Clinicaltrials.gov ID number: NCT02997228
Trials sponsors: The National Cancer Institute (NCI) and the NRG Oncology group